by Alex Watkins ONeill | Jul 7, 2026 | Content
This first randomized, quadruple-blind clinical trial of psilocybin for cocaine use disorder found that a single psilocybin dose combined with manualized psychotherapy produced more cocaine‑abstinent days, higher rates of complete abstinence, and fewer lapses over 180...
by Alex Watkins ONeill | Jun 30, 2026 | Content
A new SAMHSA advisory guides primary care providers, pediatricians, and geriatricians on identifying and treating cannabis use disorder across all life stages—from adolescence through pregnancy and older adulthood. The advisory notes that cannabis use disorder affects...
by Alex Watkins ONeill | Jun 23, 2026 | Content
About 70,000 Americans died of drug overdoses in 2025, about 14% fewer than the previous year, according to preliminary government data. It was the third straight annual drop, making it the longest decline in decades, according to recently released federal data. The...
by Alex Watkins ONeill | Jun 16, 2026 | Content
Low-risk drinking guidelines seldom incorporate quality of life (QoL). This secondary data analysis explores the relationship between drinking patterns and QoL. Study: Informing low-risk drinking guidelines: a secondary, cross-sectional data analysis of alcohol use...
by Alex Watkins ONeill | Jun 8, 2026 | Content
A new study published in the May 2026 issue of Anesthesiology exposes challenges in reversing opioid overdoses with naloxone when potent synthetic drugs like fentanyl and sufentanil are involved. Researchers found that a single dose may not fully reverse respiratory...
Recent Comments